The New York Medical Angels are willing to provide early-stage funding to companies centered on medical devices, diagnostics, research tools, and drug development. Read article in the Democrat and Chronicle
University of Rochester Medical Center researcher Richard P. Phipps, Ph.D., won a top scientific award from the pharmaceutical giant Novo Nordisk, to collaborate on a new obesity therapy based on his laboratory’s discoveries. Phipps, the Wright Family Research Professor of Environmental Medicine, is the first UR
The Center for Emerging and Innovative Sciences (CEIS) works with companies and universities to advance scientific knowledge, stimulate economies, and make cool stuff happen. Read about a few of their exciting current projects at the Democrat & Chronicle or USA Today.
Reuters has compiled a list of the 100 most innovative universities on the planet. It is no surprise to anyone that Stanford tops that list. Rochester is proud to be included, too. Read the complete story here.
The first issue of UR Ventures Technology Review is out and available here.
The 17 June installment of the Good Advice: Case Studies in Clinical Research, Regulation, and the Law will examine the fascinating history of the COX-2 litigation. Presented by M. Kerry O’Banion, MD, PhD and Thomas Jackson, JD and Immediate Past President of the University of
Camber NeuroTherapeutics Inc., founded based on discoveries made in the laboratories of Harris “Handy” A. Gelbard, M.D., Ph.D. and Stephen Dewhurst, Ph.D., plans to attack the cognitive component of neurodegenerative diseases using a completely new approach: stopping the inflammation in the brain, so-called neuroinflammation, that
Rochester, NY – May 15, 2015 – EagleDream Health, Inc., a healthcare analytics software solutions company today announced it has acquired Focused Medical Analytics, LLC, (FMA) a company specializing in data analysis to identify, understand, and address clinical variation. The acquisition strengthens EagleDream Health’s analytics solution
17 April 2015 CNN Money Panther Biotechnology, Inc. (OTC PINK: PBYA), a biotechnology company specializing in the development of enhanced therapeutics for the treatment of neoplastic disorders, is pleased to announce today that it has entered into an exclusive global license agreement with the University